AbCellera Biologics annual current ratio
2020
2021
2022
2023
2024
2025
AbCellera Biologics Current Ratio Growth & History (ABCL)
AbCellera Biologics's current ratio was 11.32 for fiscal 2025.
View full AbCellera Biologics company overviewAbCellera Biologics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 11.32 | 1.52 | +15.47% |
| 2024 | 2024-12-31 | 9.81 | 2.48 | +33.86% |
| 2023 | 2023-12-31 | 7.33 | −1.34 | −15.46% |
| 2022 | 2022-12-31 | 8.67 | 0.96 | +12.49% |
| 2021 | 2021-12-31 | 7.70 | −0.15 | −1.96% |
| 2020 | 2020-12-31 | 7.86 | — | — |
AbCellera Biologics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.77 | 1.70 | +15.33% |
| Q1 2026 | 2026-03-31 | 14.05 | 3.91 | +38.50% |
| Q4 2025 | 2025-12-31 | 11.32 | 1.52 | +15.47% |
| Q3 2025 | 2025-09-30 | 10.10 | 0.77 | +8.21% |
| Q2 2025 | 2025-06-30 | 11.07 | 0.11 | +1.01% |
| Q1 2025 | 2025-03-31 | 10.15 | 2.39 | +30.74% |
| Q4 2024 | 2024-12-31 | 9.81 | 2.48 | +33.86% |
| Q3 2024 | 2024-09-30 | 9.34 | 1.00 | +11.93% |
| Q2 2024 | 2024-06-30 | 10.96 | 3.14 | +40.05% |
| Q1 2024 | 2024-03-31 | 7.76 | −2.74 | −26.09% |
| Q4 2023 | 2023-12-31 | 7.33 | −1.34 | −15.46% |
| Q3 2023 | 2023-09-30 | 8.34 | −1.52 | −15.40% |
| Q2 2023 | 2023-06-30 | 7.83 | 2.65 | +51.32% |
| Q1 2023 | 2023-03-31 | 10.50 | 5.00 | +90.80% |
| Q4 2022 | 2022-12-31 | 8.67 | 0.96 | +12.49% |
| Q3 2022 | 2022-09-30 | 9.86 | −6.36 | −39.22% |
| Q2 2022 | 2022-06-30 | 5.17 | −7.21 | −58.23% |
| Q1 2022 | 2022-03-31 | 5.50 | −4.77 | −46.43% |
| Q4 2021 | 2021-12-31 | 7.70 | −0.15 | −1.96% |
| Q3 2021 | 2021-09-30 | 16.22 | — | — |
| Q2 2021 | 2021-06-30 | 12.39 | — | — |
| Q1 2021 | 2021-03-31 | 10.27 | — | — |
| Q4 2020 | 2020-12-31 | 7.86 | — | — |
AbCellera Biologics current ratio trends
Over the last five fiscal years, AbCellera Biologics's current ratio increased from 7.86 to 11.32, a change of 3.47. The latest reported quarter, Q2 2026, shows 12.77.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbCellera Biologics source filings ↗